Introduction {#s1}
============

Knee osteoarthritis (KOA), one of the most common degenerative musculoskeletal diseases involving chronic pain and dysfunction ([@B10]), is characterized by inflammation of the synovial membrane and progressive destruction of the articular cartilage ([@B3]; [@B28]). KOA has been reported to be one of the top 10 causes of physical disability ([@B33]); however, no treatment methods developed to date have been able to reverse or alter the progression of KOA ([@B7]). Although the pathogenesis of KOA remains unclear, inflammation is widely regarded to be an extremely important factor ([@B13]; [@B3]; [@B46]). Cartilage damage has been reported to induce synovial inflammation ([@B38]), and chondrocyte‐mediated inflammatory responses play a key role in the development and progression of osteoarthritis (OA) ([@B20]). Therefore, effective inhibition of chondrocyte inflammation may play a role in reversing or altering the progression of OA.

Many signaling pathways play a crucial role in the development and progression of OA. The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway is widely distributed in various parts of the body, mediating immune responses, inflammation, and stress responses ([@B25]; [@B41]; [@B47]). In general, NF-κB is in an inactive state because its dimer can interact with an inhibitory protein, inhibitory protein of NF-κB (IKB), which binds to a trimer complex under non-stimulated conditions. After receiving stimulus, IKB kinase is activated by phosphorylating the IKB protein, thereby dissociating from the trimer, and then activating the NF-κB signaling pathway. Activated NF-κB can induce excessive expressions of interleukin (IL)-1β and matrix metalloproteinases (MMPs), which play key roles in inflammation and extracellular matrix (ECM) degradation ([@B37]; [@B14]). In addition, IL-1β can induce the synthesis of inducible nitric oxide synthase (iNOS) and stimulate the production of nitric oxide (NO), cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), and tumor necrosis factor- alpha (TNF-α) ([@B12]; [@B4]; [@B44]; [@B11]), which is associated with OA progression. Furthermore, IL-1β can also stimulate the release of MMPs and a disintegrin and MMP with thrombospondin motifs (ADAMTS) ([@B37]); MMPs and ADAMTS can significantly promote the degradation of ECM, which further aggravates the progression of OA.

Cinnamic aldehyde (CA) is an α,β-unsaturated aldehyde extracted from the traditional Chinese herbal medicine cinnamon (*Cinnamomum verum* J.Presl). The chemical structure of CA is shown in [**Figure 1A**](#f1){ref-type="fig"}. Several studies have suggested that cinnamon extract has anti-inflammatory, antioxidant, antidiabetic, antipyretic, antibacterial, and anticancer properties ([@B31]; [@B21]; [@B42]; [@B45]; [@B5]). However, the anti-inflammatory effect of CA on OA remains unknown. Therefore, the aim of the present study was to investigate the anti-inflammatory effect and underlying mechanism of CA in chondrocyte inflammation and degeneration.

![Effect of cinnamic aldehyde (CA) on the viability of human osteoarthritis (OA) chondrocytes. **(A)** The chemical structure of CA. **(B)** Human OA chondrocytes were pretreated with different concentrations of CA (0, 5, 10, 20, 50,100, and 200 μM) for 24 h and evaluated using the CCK-8 assay.](fphar-11-00949-g001){#f1}

Methods {#s2}
=======

Articular Chondrocyte Isolation and Culture {#s2_1}
-------------------------------------------

The present study adhered to the principles of the Declaration of Helsinki, and the protocol was approved by the ethics committee of the Third Affiliated Hospital of Beijing University of Chinese Medicine (Beijing, China). All human clinical samples were obtained from patients who underwent total knee replacement surgery at the Third Affiliated Hospital of Beijing University of Chinese Medicine. Deidentified, discarded human cartilage samples were used for this study. Articular cartilage samples were collected from 6 patients who fulfilled the American College of Rheumatology classification criteria ([@B34]) for the diagnosis of OA (2 men and 4 women; 62 to 73 years of age). Briefly, cartilage samples were washed in phosphate-buffered saline (PBS), which included an antibiotic mixture (penicillin/streptomycin, Invitrogen/Thermo-Fisher Scientific, Waltham, MA, USA) 3 times and then diced into 1×1×1 mm^3^ pieces. These joint cartilage pieces were digested with 0.25% trypsin-EDTA solution (Solarbio, China) for 40 min and then overnight at 37°C in 0.2% type II collagenase and centrifuged at 176 g for 5 min, after which the supernatant was discarded. The pellet was resuspended in Dulbecco's modified Eagle medium F12 (Hyclone, South Logan, UT, USA) with 10% fetal bovine serum (ABW, Uruguay) and 1% antibiotic mixture (penicillin/streptomycin, Invitrogen, USA). Finally, cells were plated at a density of 1 × 105 cells/ml in 6-well plates and incubated in a humidified atmosphere of 5% CO~2~ at 37°C. The media were changed every 2 or 3 days. Cells were passaged at 80% to 90% confluence using 0.25% trypsin-EDTA solution (passage 0). One-half of the articular chondrocytes at passage 0 were preserved at −80°C; the remainder were cultured and passaged for subsequent studies. Only passages 1 to 5 were used in the present study to avoid phenotype loss. In a cell viability experiment, the potential toxicity of CA (Sigma-Aldrich, St Louis, MO, USA) on chondrocytes was assessed using a commercially available CCK-8 assay kit (Dojindo Molecular Technologies Inc, Tokyo, Japan) according to the manufacturer's instructions.

Cell Viability {#s2_2}
--------------

Cell viability was evaluated using the CCK-8 assay in accordance with the manufacturer's instructions. Human OA chondrocytes were cultured in 96-well plates at a density of 8 × 10^3^ cells per well for 24 h and then pretreated with different concentrations of CA (0, 5, 10, 20, 50, 100, and 200 μmol/L) for an additional 24 h. The next day, the supernatant of each group was aspirated, and then washed with PBS, a medium containing 10-μL CCK-8 was added to each well and incubated at 37°C for 3 h. The optical density of each well was read at a wavelength of 450 nm by using a microplate reader (Leica Microsystems, Mannheim, Germany). Chondrocytes treated with dimethyl sulfoxide in the CCK-8 and subsequent *in vitro* experiments were used as the control group.

NF-κB Overexpression {#s2_3}
--------------------

Human OA chondrocytes were transiently transfected with a NF-κB p65 plasmid or control vector (TSINGKE, BeiJing, China) for 24 h by using Lipofectamine 2000 (Invitrogen, USA) in accordance with the manufacturer's instructions. Chondrocytes were pretreated with 20- and 50-μM CA for 24 h and then stimulated with LPS (10 μg/ml, Bioruler, Danbury, CT, USA) for 24 h. Messenger RNA (mRNA) and protein were collected for subsequent experiments.

Real-Time Quantitative Polymerase Chain Reaction Analysis {#s2_4}
---------------------------------------------------------

Total RNA was extracted from chondrocytes by using the TRIzol reagent in accordance with the manufacturer's instructions. Concentration was determined at 260 nm by using an ultraviolet spectrophotometer (NanoDrop 2000, Thermo-Fisher Scientific, Waltham, MA, USA), and the 260/280 ratio was calculated to verify quality and purity. Complementary DNA was generated by using a commercially available kit (PrimeScript Reverse Transcription kit, Takara Bio Inc, Kusatsu, Shiga Prefecture, Japan) under the following conditions: 15 min at 50°C and 5 sec at 85°C. Real-time quantitative polymerase chain reaction (RT-qPCR) was performed using a thermocycler (Mx3000P; Stratagene, La Jolla, CA, USA) and SYBR Premix Ex Taq II Kit (Takara Bio Inc, Japan) under the following conditions: 10 min at 95°C, followed by 40 cycles at 95°C for 15 s, and at 60°C for 1 min. Each gene analysis was performed in triplicate in accordance with the manufacturer's recommendations. The RT-qPCR primers are listed in [**Table 1**](#T1){ref-type="table"}. Data were analyzed using the 2-ΔΔCT method.

###### 

Reverse transcription-quantitative polymerase chain reaction primers.

  ------------------ -------------------------
  Human-IL6-F        ACTCACCTCTTCAGAACGAATTG
  Human-IL6-R        CCATCTTTGGAAGGTTCAGGTTG
  Human-IL-1β-F      CTGTCCTGCGTGTTGAAAGA
  Human-IL-1β-R      TTGGGTAATTTTTGGGATCTACA
  Human-TNF-a-F      CCTCTCTCTAATCAGCCCTCTG
  Human-TNFa-R       GAGGACCTGGGAGTAGATGAG
  Human-MMP13-F      TCCTGATGTGGGTGAATACAATG
  Human-MMP13-R      GCCATCGTGAAGTCTGGTAAAAT
  Human-COX2-F       CTGGCGCTCAGCCATACAG
  Human-COX2-R       CGCACTTATACTGGTCAAATCCC
  Human-ADAMTS5- F   GAACATCGACCAACTCTACTCCG
  Human-ADAMTS5-R    CAATGCCCACCGAACCATCT
  Human-actin-F      GATTCCTATGTGGGCGACGA
  human-actin-R      AGGTCTCAAACATGATCTGGGT
  ------------------ -------------------------

Western Blot Analysis {#s2_5}
---------------------

Proteins were harvested from chondrocytes by using radioimmunoprecipitation assay (RIPA) and phenylmethylsulfonyl fluoride (PMSF) buffer (Beyotime Biotechnology, Shanghai, China), and 0.2-ml buffer was added in each group, left at 4°C for 20 min and centrifuged at 12000 rpm for 15 min. Then, the supernatant was discarded to determine the protein concentration in each sample by using a commercially available BCA protein assay kit (Thermo-Fisher Scientific, USA). A loading buffer was then added, mixed well, exposed to a metal bath at 95°C for 5 min, and stored at −80°C after dispensing. Western blot (WB) analysis was performed in accordance with a method described previously ([@B7]; [@B8]). Briefly, equal amounts of protein (40 μg) were separated using sodium-dodecyl polyacrylamide gel electrophoresis, loaded onto the 8%--12% separation gel according to the target molecular weight, and then transferred onto a polyvinylidene fluoride (PVDF) membrane. The PVDF membranes were incubated with a blocking buffer (5% nonfat milk in TBST), labeled with primary antibodies (Abcam, Cambridge, MA, USA) overnight at 4°C, washed 3 times with TBST, and incubated with horseradish peroxidase-labeled secondary antibodies (Abcam, USA). Primary antibodies against IL-1β, TNF-α, IL-6, and MMP-13 were purchased from Cell Signaling Technology (Cambridge, MA, USA); ADAMTS-5, p65, and IKB-α were purchased from Abcam (Cambridge). Images were developed after reaction with a high-sensitivity chemiluminescence reagent (Peprotech, London, United Kingdom).

Enzyme-Linked Immunosorbent Assay {#s2_6}
---------------------------------

Briefly, chondrocyte supernatants were collected by centrifugation at 176 g for 5 min. The proteins of the chondrocyte supernatants in each group were also extracted with RIPA and PMSF buffer, and then quantified with the BCA kit. Cytokine concentrations (IL 1β, IL 6, and TNF-α) were determined using a commercially available enzyme-linked immunosorbent assay (ELISA) kit in accordance with the manufacturer's instructions (Proteintech Group Inc, Rosemont, IL, USA).

Statistical Analyses {#s2_7}
--------------------

All the experiments were performed at least 3 times independently, and data are reported as mean ± standard deviation. All the analyses were performed using SPSS version 23.0 (IBM Corporation, Armonk, NY, USA). Differences between groups were compared using one-way analysis of variance, and a p values of \<0.05 was considered statistically significant.

Results {#s3}
=======

Cytotoxicity Assay: Effect of CA on Human OA Chondrocyte Viability {#s3_1}
------------------------------------------------------------------

The potential cytotoxicity of different concentrations of CA (0, 5, 10, 20, 50, 100, and 200 μM) on human OA chondrocytes was examined using the CCK-8 assay. The results suggested that low concentrations of CA (10, 20, and 50 μM) promoted chondrocyte viability, while high concentrations (100 and 200 μM) of CA could reversed it ([**Figure 1B**](#f1){ref-type="fig"}). Therefore, CA at concentrations of 10, 20, 50 μmol/L were used in subsequent experiments.

CA Inhibited the Expression of Proinflammatory Cytokines in LPS-Induced Human OA Chondrocytes {#s3_2}
---------------------------------------------------------------------------------------------

The effects of CA on proinflammatory cytokines (IL-1β, IL-6, and TNF-α) on LPS-induced human OA chondrocytes were investigated using RT-qPCR, WB, and ELISA. As shown in [**Figure 2**](#f2){ref-type="fig"}, compared with the normal group, LPS-induced chondrocytes exhibited significantly increased mRNA and protein expression levels of IL-1β, IL-6, and TNF-α (p \< 0.05). However, pretreatment with different concentrations of CA (10, 20, and 50 μM) significantly downregulated the mRNA and protein expression levels of IL-1β, IL-6, and TNF-α in a dose-dependent manner (p \< 0.05).

![Effect of cinnamic aldehyde (CA) on lipopolysaccharide (LPS)-induced interleukin (IL)-1β, IL-6, and tumor necrosis factor-alfa (TNF-α) expression in human osteoarthritis (OA) chondrocytes. Human OA chondrocytes were pretreated for 24 h with various concentrations of CA (10, 20, and 50 μM) and then stimulated or not stimulated with LPS (10 μg/ml) for 24 h. **(A)** Messenger RNA (mRNA) expression levels of IL-1β, IL-6, and TNF-α were determined using real-time quantitative polymerase chain reaction (RT-qPCR). **(B)** Enzyme-linked immunosorbent assay results for IL-1β, IL-6, and TNF-α in chondrocyte supernatants. **(C, D)** Protein expression levels were assayed by Western blot and quantification analysis using Image J software. ^\#^P \< 0.01 compared with control group; \*P \< 0.05, \*\*P \< 0.01 compared with LPS group. All experiments were performed at least 3 times independently ( n = 3).](fphar-11-00949-g002){#f2}

CA Inhibited the Expressions of MMP13 and ADAMTS-5 in LPS-Induced Human OA Chondrocytes {#s3_3}
---------------------------------------------------------------------------------------

Subsequently, the effects of CA on the mRNA and protein levels of MMP13 and ADAMTS-5 were assessed. As presented in [**Figure 3A**](#f3){ref-type="fig"}, LPS-induced chondrocytes exhibited markedly upregulated mRNA expression levels of MMP13 and ADAMTS-5 (p \< 0.05), whereas the expression levels of MMP13 and ADAMTS-5 were significantly reduced in the CA pretreated group in a dose-dependent manner (p \< 0.05). Similarly, WB analysis demonstrated that CA decreased the protein upregulation of MMP13 and ADAMTS-5 (p \< 0.05; [**Figures 3B, C**](#f3){ref-type="fig"}). Therefore, 20- and 50-μM CA were used in the subsequent experiments.

![Effect of cinnamic aldehyde (CA) on lipopolysaccharide (LPS)-induced matrix metalloproteinase (MMP)13 and a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS-5) expression in human osteoarthritis (OA) chondrocytes. Human OA chondrocytes were pretreated for 24 h with various concentrations of CA (10, 20, and 50 μM) and then stimulated or not stimulated with LPS (10 μg/ml) for 24 h. **(A)** Messenger (mRNA) expression levels of MMP13 and ADAMTS-5 were determined using real-time quantitative polymerase chain reaction (RT-qPCR). **(B, C)** Protein expression levels were assayed using Western blot and quantification analysis with Image J software. ^\#^P \< 0.01 compared with control group; \*P \< 0.05, \*\*P \< 0.01 compared with LPS group. All experiments were performed at least 3 times independently (n = 3).](fphar-11-00949-g003){#f3}

CA Inhibited Activation of the NF-κB Pathway in LPS-Induced Human OA Chondrocytes {#s3_4}
---------------------------------------------------------------------------------

To further investigate the potential anti-inflammatory mechanism of CA, biomarkers of the NF-κB pathway (p65 and IKB-α) were detected using a WB assay. As presented in [**Figure 4**](#f4){ref-type="fig"}, LPS induced significant upregulation and expression of p65 in human OA chondrocytes (p \< 0.05). By contrast, pretreatment with various concentrations of CA (20 and 50 μM) significantly decreased the expression level of p65. In addition, stimulation of chondrocytes with LPS significantly inhibited the expression of IKB, while pretreatment with CA (20 and 50 μM) significantly promoted the expression of IKB (p \< 0.01).

![Effect of cinnamic aldehyde (CA) on lipopolysaccharide (LPS)-induced nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation in human osteoarthritis (OA) chondrocytes. Human OA chondrocytes were pretreated for 24 h with different concentrations of CA (20, 50 μM) and then stimulated or not stimulated with LPS (10 μg/ml) for 24 h. The protein expression levels of p65, inhibitory protein of NF-κB (IKB-α) were determined using Western blot assay **(A)** and then quantified **(B, C)**. ^\#^P \< 0.01 compared with control group; \*\*P \< 0.01 compared with LPS group. All experiments were performed at least 3 times independently (n = 3).](fphar-11-00949-g004){#f4}

CA Reversed Inflammation *via* the NF-κB Pathway {#s3_5}
------------------------------------------------

To demonstrate the necessity of the NF-κB pathway in CA to reduce cartilage damage and inhibit inflammation, chondrocytes were transiently transfected with NF-κB p65 plasmid or control vector for 24 h. As presented in [**Figure 5A**](#f5){ref-type="fig"}, stimulation of chondrocytes with the NF-κB p65 plasmid significantly activated the NF-κB signal pathway. As is shown in [**Figures B--D**](#f5){ref-type="fig"}, after induction with LPS, the p65 expression level was significantly upregulated and the IKB expression level downregulated in the LPS + overexpression (OE) group, while CA rescued the p65 and IKB expressions (p \< 0.05).

![Cinnamic aldehyde (CA) reverse inflammation *via* the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. Human osteoarthritis (OA) chondrocytes were transiently transfected with a NF-kB p65 plasmid or an empty vector for 24 h using Lipofectamine 2000 (Invitrogen, USA). **(A)** Chondrocytes were pretreated with 20 μM and 50 μM CA for 24 h and then stimulated with lipopolysaccharide (LPS) for 24 h. **(B--D)** Treatment with an NF-κB p65 plasmid significantly activated the NF-κB signal pathway. Pretreatment with CA rescued the expression of p65 and inhibitory protein of NF-κB (IKB-α). OE, overexpression; 20, 20 μM CA; 50, 50 μM CA. ^\#^P \< 0.01 compared with LPS group; \*P \< 0.05, \*\*P \< 0.01 compared with LPS+OE group. All experiments were performed at least 3 times independently (n = 3).](fphar-11-00949-g005){#f5}

Discussion {#s4}
==========

Cartilage degeneration is one of the main pathological manifestations of OA. The results of this study indicate that pretreatment with CA significantly inhibited the productions of IL-1β, IL-6, and TNF-α induced by LPS in human OA chondrocytes, and significantly reduced the expression levels of MMP-13 and ADAMTS-5. Furthermore, pretreatment with CA inhibited the expressions of NF-κB, p65, and IKB-α induced by LPS in chondrocytes. Pretreatment with CA significantly reversed the expressions of p65 and IKB-α in LPS-induced human OA chondrocytes when transfected with a NF-κB p65 plasmid.

Cinnamon, a common traditional Chinese medicine, is widely used in the treatment of low back pain, diabetes, arthritis, and cardiovascular diseases. CA is an active ingredient extracted from cinnamon, and its anti-inflammatory property is one of its most important characteristics. Cinnamon extract can inhibit the production of prostaglandins by inhibiting COX, thereby inhibiting inflammation ([@B6]). CA exerts anti-inflammatory and antioxidative effects in an LPS-induced mouse macrophage cell line ([@B16]). In the LPS-induced RAW 264.7 cell line, trans-cinnamaldehyde decreased the transcriptional activity of NF-κB by inhibiting its DNA binding activity ([@B35]). CA can also inhibit *Aggregatibacter actinomycetemcomitans*-induced inflammation by activating autophagy ([@B9]). In addition, CA can modulate nuclear factor erythroid 2-related factor 2 (Nrf2) and then antioxidative stress ([@B17]; [@B2]). Reactive oxygen species (ROS) can activate the NF-KB signaling pathway and release more inflammatory factors ([@B18]), and the property of the activated NF-KB signaling pathway induced by CA can be interrupted by dithiothreitol ([@B27]; [@B16]). However, to our knowledge, no published studies have investigated the therapeutic mechanism of CA in OA. In this study, we validated the effect of CA on chondrocyte inflammation and degeneration *in vivo* and found that CA can significantly inhibit the expressions of inflammatory factors and reduce the loss of ECM.

Inflammatory cytokines play important roles in promoting the pathogenesis of OA. Among the inflammatory cytokines, the interleukin family, especially IL-1β and IL-6, has been considered to play a critical role in the pathological development of OA ([@B37]; [@B22]). It can stimulate the productions of the inflammatory cytokines NO, iNOS, and prostaglandin E2 (PGE2), which are associated with OA progression ([@B26]; [@B40]). TNF-α is another inflammatory cytokine that drives the pathogenesis and progression of OA ([@B24]). TNF-α can stimulate the expressions of MMPs, ADAMTS, and chondrocyte dedifferentiation markers ([@B32]; [@B39]). MMP13, a member of the MMPs family of enzymes that cleave protein substrates based on a conserved mechanism, promotes cartilage turnover and breakdown, degrades components of the ECM, and plays an important pathological role during inflammation in OA ([@B1]; [@B19]; [@B48]). ADAMTS consists of secreted zinc MMPs with thrombospondin motifs, another family with an important role in the breakdown type II collagen and proteoglycans that constitute the main structure of the ECM ([@B43]; [@B29]). ADAMTS-5 is a member of the ADAMTS family and plays a primary role in degradation of ECM in OA ([@B43]; [@B23]). Therefore, inhibiting the expressions of proinflammatory cytokines (IL-1β, IL-6, and TNF-α) and reducing the loss of collagen-II and ECM may have a significant mitigating effect on the progression of OA.

To further investigate the potential anti-inflammatory and chondroprotective mechanisms of CA, we examined the expressions of the NF-κB signaling pathway biomarkers in pretreatment with or without CA in LPS-induced human OA chondrocytes. The NF-κB pathway is one of the major catabolic pathways involved in the pathogenesis of OA and plays a key role in the regulation of inflammatory mediators associated with OA ([@B36]). Upon stimulation, the activated NF-κB pathway regulated the expressions of an array of cytokines that induce ECM destruction, aggravating the OA process ([@B30]). Therefore, inhibition of the NF-κB signaling pathway activity may be a potential therapeutic target for OA. The results of the present study demonstrated that CA significantly inhibited the NF-κB signaling pathway activity in LPS-induced human OA chondrocytes. Moreover, we found that CA specifically inhibited the activity of the NF-kB signaling pathway when transfected with a NF-κB p65 plasmid in human OA chondrocytes, which is consistent with the results of several previous studies ([@B35]; [@B15]; [@B30]).

Collectively, the results of this study were the first to demonstrate the anti-inflammatory and chondroprotective effects of CA in an *in vivo* model. In LPS-induced human OA chondrocytes, CA significantly decreased the expression levels of IL-1β, IL-6, TNF-α, MMP13, and ADAMTS-5 by inhibiting the NF-κB signaling pathway. As such, CA may be an ideal therapeutic agent for treating OA.
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